Johnson & Johnson kicks off trial for one shot Covid-19 vaccine

Johnson & Johnson is beginning a huge final study to try to prove if the single-dose vaccine can protect against the coronavirus. Picture: Cheryl Gerber 

Johnson & Johnson has kicked off a final 60,000-person trial of a single-shot Covid vaccine that potentially would simplify the distribution of millions of doses compared with leading rivals using two doses.

The company expects results of the Phase III trial by year-end or early next year, Paul Stoffels, J&J’s chief scientific officer, said in a press conference with officials from the National Institutes of Health and the Trump administration.